Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

SAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference:

Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

Inhibrx Announces Participation in Upcoming Scientific Conference

Mon, 02 Mar 2026 16:00:00 -0500

Form 8-K Inhibrx Biosciences, For: Feb 23

Mon, 23 Feb 2026 09:00:00 -0500

si-local-file:///var/storage/secattach/20260223/26040205.html

Form 8-K Inhibrx Biosciences, For: Feb 23

Mon, 23 Feb 2026 09:00:00 -0500

si-local-file:///var/storage/secattach/20260223/26040205.html

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP

Tue, 17 Feb 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260217/26013626.html

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP

Tue, 17 Feb 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260217/26013626.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Wed, 11 Feb 2026 13:34:00 -0500

si-local-file:///var/storage/secattach/20260211/25982247.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Wed, 11 Feb 2026 13:34:00 -0500

si-local-file:///var/storage/secattach/20260211/25982247.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Wed, 11 Feb 2026 13:34:00 -0500

si-local-file:///var/storage/secattach/20260211/25982248.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Wed, 11 Feb 2026 13:34:00 -0500

si-local-file:///var/storage/secattach/20260211/25982248.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: BlackRock, Inc.

Wed, 21 Jan 2026 12:32:00 -0500

si-local-file:///var/storage/secattach/20260121/25873773.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: BlackRock, Inc.

Wed, 21 Jan 2026 12:32:00 -0500

si-local-file:///var/storage/secattach/20260121/25873773.html

Inhibrx's (INBX) 'Data Disclosures Leave us Guessing' - Citizens

Wed, 17 Dec 2025 04:58:03 -0500

Citizens analyst Reni Benjamin reiterated a Market Perform rating on Inhibrx Biosciences (NASDAQ: INBX).

The analyst commented, "Inhibrx's limited data disclosures and lack of management communication leave us guessing. No new data raises doubts about response durability and strength. The company's claim of insufficient data maturity suggests either slow-emerging responses, limited benefit, or an impact on the PFS tails that require further follow-up. For INBRX-109, expansion cohorts in mCRC and ES are advancing, with mature PFS data expected in 2Q26."

For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences

INHIBRX Biosciences updates progress on cancer drug trials

Tue, 16 Dec 2025 17:00:39 -0500

Inhibrx Biosciences, Inc. (NASDAQ: INBX) provided updates on clinical trials for two cancer treatments, including enrollment progress and expected data timelines for multiple patient populations.

The company has recruited 46 of 60 patients in the Phase 2 portion of its INBRX-106 trial combined with Keytruda for first-line treatment of unresectable or metastatic head and neck squamous cell carcinoma. Enrollment is expected to complete during the first quarter of 2026. The trial targets patients with tumor PD-L1 CPS expression of 20 or greater who have not received prior systemic therapy.

Inhibrx completed enrollment of 34 patients in November 2025 for a Phase 1/2

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Tue, 16 Dec 2025 17:00:00 -0500

SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda^® (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda. The Company also provided a

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Tue, 16 Dec 2025 17:00:00 -0500

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Tue, 16 Dec 2025 17:00:00 -0500

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Tue, 16 Dec 2025 17:00:00 -0500

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Tue, 16 Dec 2025 17:00:00 -0500

StreetInsider.com News Articles

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference

Form 8-K Inhibrx Biosciences, For: Feb 23

Form 8-K Inhibrx Biosciences, For: Feb 23

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: MORGAN STANLEY

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: BlackRock, Inc.

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: BlackRock, Inc.

Inhibrx's (INBX) 'Data Disclosures Leave us Guessing' - Citizens

INHIBRX Biosciences updates progress on cancer drug trials

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program